New cancer treatment using extended half-life GlyTR1 with immune checkpoint inhibitors
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
This study is exploring a new way to help people with hard-to-treat cancers by using a special treatment that combines a new type of immune therapy with existing cancer treatments, aiming to better target and attack cancer cells for those who have limited options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glytr Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project ID | NIH-11159869 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating non-resectable recurrent or metastatic solid cancers by combining extended half-life GlyTR1 with immune checkpoint blockade therapies. The focus is on developing antigen-targeting cancer immunotherapies, particularly bi-specific antibodies, which can engage the immune system to attack cancer cells more effectively. The study aims to identify safe antigen-specific immunotherapies that can be used for patients with limited treatment options, especially those with solid tumors that express unique carbohydrate antigens. By targeting these specific antigens, the research hopes to improve treatment outcomes for patients with aggressive cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with non-resectable recurrent or metastatic solid cancers who have exhausted other treatment options.
Not a fit: Patients with early-stage cancers or those who have not yet undergone other treatment modalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with difficult-to-treat solid tumors.
How similar studies have performed: Other research has shown promise in using bi-specific antibodies for cancer treatment, indicating that this approach has potential based on previous successes.
Where this research is happening
San Carlos, UNITED STATES
- Glytr Therapeutics, INC. — San Carlos, United States (Active)
Researchers
- Principal investigator: Demetriou, Michael — Glytr Therapeutics, INC.
- Study coordinator: Demetriou, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.